You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Y2 and Y4 Agonists in Obesity

    SBC: P2D, INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): The purpose of the proposed studies is to assess the feasibility of developing a novel Neuropeptide Y (NPY) obesity treatment. Extensive preclinical and clinical studies indicate that NPY receptors are important mediators of appetite and obesity. The proposed Specific Aims will determine if chronic treatment with selective NPY Y2 or Y4 receptor agonists demonst ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Venous Thromboembolism Risk Marker Assay

    SBC: Gamma Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): The application's broad, long-term objectives are to develop a rapid, high-throughput clinical assay for 3' fibrinogen that will be used to assess the risk of a patient developing venous thromboembolism. This assay will guide clinical management, particularly the use of long-term anticoagulant therapy for patients. The utility of this assay will be the identifi ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. USING SYNTHETIC PEPTIDES REPRESENTING PORTIONS OF VIRAL STRUCTURAL PROTEINS AS VACCINES AGAINST THE VIRUS.

    SBC: Syngene Products And Research            Topic: N/A

    USING SYNTHETIC PEPTIDES REPRESENTING PORTIONS OF VIRAL STRUCTURAL PROTEINS AS VACCINES AGAINST THE VIRUS. USING AUTOMATED SYNTHESIZERS, PEPTIDES OF ABOUT 15 AMINO ACIDS IN LENGTH WILL BE SYNTHESIZED WHICH CORRESPOND TO REGIONS OF A 267 AMINO ACID SEGMENT OF THE FELINE PANLEUKOPENIA VIRAL PROTEINS. THIS SEGMENT IS KNOWN FROM OUR PREVIOUS WORK TO CONTAIN IMMUNOGENIC DETERMINANTS WHICH RAISE NEUTRAL ...

    SBIR Phase I 1983 Department of Health and Human Services
  4. Use Mobile Devices and Cloud Computing Platforms for Real-time Data Solutions in

    SBC: INVENUX, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a botanical drug for use in children that prevents theinexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Unique Antimicrobial Catheter to Prevent Urinary Tract Infections

    SBC: NORTHWEST MEDIA, INC            Topic: NICHD

    DESCRIPTION (provided by applicant): In this Phase I we will develop and evaluate the first unit of an online serious game for foster and primary parents of neglected children. The goal of the training is to learn how parents in these two historically compartmentalized roles can improve their parenting by working cooperatively. Research shows that cross-training strategies can optimize the chances ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. TOPIC 323 PHASE I; DEVELOPMENT OF RADIATION MODULATORS FOR USE DURING RADIOTHERAP

    SBC: SuviCa, Inc.            Topic: NCI

    The long-term goal of this proposal is to discover and develop small molecule drugs against Head and Neck Cancers (HNC). The focus is on drug candidates that target processes critical for repopulation after radiation treatment. The current proposal is to perform preliminary pharmacokinetics and toxicity studies and test the efficacy of a proprietary drug candidate on preclinical models of human HN ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Throughmask ElectroEtching for Cost-Effective Nitinol Stent Fabrication

    SBC: Faraday Technology, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Description Faraday Technology, Inc. proposes to develop the Faradayic ElectroEtching Process, based on pulsed electrolytic through-mask etching of nitinol stents, for rapid stent fabrication while maintaining pattern fidelity in a neutral, aqueous, non-toxic electrolyte. This process will enable stent manufacturing while minimizing process control difficultie ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. The Simultaneous Acquisition of Auditory Transient and Steady State Evoked Potent

    SBC: Intelligent Hearing Systems Corp.            Topic: NIDCD

    DESCRIPTION (provided by applicant): This project aims to develop a device capable of acquiring transient and steady state auditory evoked potenlatials (AEPs) simultaneously using an efficient and advanced processing technique. The proposed technique willbe implemented as a software module on Intelligent Hearing Systems' (IHS) evoked potential system platform. Auditory Transient Responses (AT ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Thermostable Sublingual Measles Vaccine Dry Wafers

    SBC: AKTIV-DRY            Topic: N/A

    "Measles is a highly contagious, human disease that is spread by the respiratory route, and, in the developing world, remains a leading cause of death due to vaccine-preventable infectious diseases in children younger than 5 years. The most recent estimates are that there were 139,300 deaths worldwide in 2010 due to measles. Research priorities to help achieve the goals of controlling, and eventua ...

    SBIR Phase I 2013 Department of Health and Human ServicesCenters for Disease Control and Prevention
  10. Therapeutic Protein C Activator for Myocardial Ischemia

    SBC: Aronora, Inc            Topic: NHLBI

    DESCRIPTION (provided by applicant): Rapidly progressing occlusion of the coronary artery and the subsequent acute myocardial ischemia is the most prevalent primary cause of acute myocardial infarction (AMI) and death in the United States. Early recanalization and antithrombotic therapy promotes reperfusion and improves outcomes when administered before completion of the infarct. However, most he ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government